<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Unfolded Protein Response (UPR) Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Unfolded Protein Response (UPR) Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
The unfolded protein response (UPR) is a critical adaptive signaling network activated by endoplasmic reticulum (ER) stress, which occurs when protein folding demand exceeds capacity. In neurons—post-mitotic cells with exceptionally high protein synthesis rates—the UPR plays a dual role: promoting cellular survival through adaptive mechanisms or triggering apoptosis when stress becomes chronic and irremediable. This page provides comprehensive coverage of UPR biology in neurons, its dysregulation in neurodegenerative diseases, and emerging therapeutic strategies targeting this pathway. [@hetz2012][@wang2014][@harris2019]
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Unfolded Protein Response (UPR) Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Unfolded Protein Response (UPR) Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
The unfolded protein response (UPR) is a critical adaptive signaling network activated by endoplasmic reticulum (ER) stress, which occurs when protein folding demand exceeds capacity. In neurons—post-mitotic cells with exceptionally high protein synthesis rates—the UPR plays a dual role: promoting cellular survival through adaptive mechanisms or triggering apoptosis when stress becomes chronic and irremediable. This page provides comprehensive coverage of UPR biology in neurons, its dysregulation in neurodegenerative diseases, and emerging therapeutic strategies targeting this pathway. [@hetz2012][@wang2014][@harris2019]
The endoplasmic reticulum serves as the primary site for protein folding, lipid synthesis, and calcium storage in eukaryotic cells. When misfolded proteins accumulate in the ER lumen—a condition termed "ER stress"—cells activate a coordinated signaling network known as the unfolded protein response (UPR). This adaptive program aims to restore proteostasis by: (1) attenuating protein translation to reduce folding burden, (2) upregulating chaperone genes to enhance folding capacity, and (3) activating ER-associated degradation (ERAD) to clear misfolded proteins. [@fourie2018]
Neurons are particularly vulnerable to ER stress due to several anatomical and physiological factors. First, neurons have high metabolic demands and continuous protein synthesis requirements for synaptic function, neurotransmitter release, and axonal transport. Second, neurons are long-lived cells that must maintain proteostasis over decades, making them susceptible to age-related protein aggregation. Third, the unique architecture of neurons—with extensive axonal and dendritic processes—creates challenges for protein quality control that other cell types do not face. Finally, neurons have limited regenerative capacity compared to proliferating cells, making the decision between survival and apoptosis particularly consequential.
The UPR is mediated by three ER transmembrane sensors: IRE1 (inositol-requiring enzyme 1), PERK (PKR-like ER kinase), and ATF6 (activating transcription factor 6). Each sensor is bound to the ER chaperone BiP (binding immunoglobulin protein, also known as GRP78) under normal conditions, which maintains them in an inactive state. Upon ER stress, BiP preferentially binds misfolded proteins, releasing the three sensors to initiate their respective signaling cascades. This elegant mechanism allows rapid response to ER stress while minimizing basal activity. [@hetz2012]
IRE1 is a dual-function protein with a kinase domain and an endoribonuclease domain. Upon activation, IRE1 undergoes oligomerization and autophosphorylation, activating its RNase activity to splice the XBP1 (X-box binding protein 1) mRNA. This unconventional splicing removes a 26-nucleotide intron, producing a frameshift that translates into a potent transcription factor, XBP1s (spliced XBP1). XBP1s then translocates to the nucleus and upregulates a broad program of genes involved in ER chaperone expression, lipid synthesis, ERAD, and autophagy. [@sato2019][@urra2023]
In neurons, XBP1s has been shown to have neuroprotective properties in multiple contexts. Loss of XBP1 in dopaminergic neurons renders mice more susceptible to MPTP-induced Parkinson's disease, while XBP1 overexpression protects against alpha-synuclein toxicity. Additionally, XBP1s promotes mitochondrial function through PGC-1α co-activation, linking ER stress response to cellular energetics. However, prolonged IRE1 activation can lead to regulated IRE1-dependent decay (RIDD), which degrades ER-localized mRNAs and can contribute to cellular dysfunction when uncontrolled. [@sato2019]
PERK is an ER-resident eIF2α kinase that phosphorylates the alpha subunit of eukaryotic initiation factor 2 (eIF2α) in response to ER stress. This phosphorylation globally attenuates protein translation while selectively promoting translation of specific mRNAs containing upstream open reading frames (uORFs), such as ATF4 (activating transcription factor 4). ATF4 induces expression of genes involved in amino acid metabolism, antioxidant response, and autophagy. [@kim2019]
While transient PERK activation is adaptive, chronic PERK signaling can become neurotoxic. PERK-mediated eIF2α phosphorylation is prolonged in neurons from Alzheimer's disease patients and in mouse models of amyloid pathology. The sustained translational repression disrupts synaptic protein synthesis, contributing to memory deficits. Moreover, PERK activates CHOP (C/EBP homologous protein), a pro-apoptotic transcription factor that downregulates anti-apoptotic Bcl-2 family proteins and promotes oxidative stress. [@kim2019][@chitnis2022]
ATF6 is a type II ER transmembrane protein that, upon ER stress, traffics to the Golgi apparatus where it is cleaved by S1P and S2P proteases. The cleaved cytosolic fragment (ATF6f) translocates to the nucleus and activates transcription of ER chaperone genes, including BiP, GRP94, and protein disulfide isomerase (PDI) family members. ATF6 also upregulates components of the ERAD machinery. [@diego2019]
In neurons, ATF6 has emerged as a neuroprotective branch of the UPR. ATF6 activation is observed in brain tissue from Alzheimer's disease and Parkinson's disease patients, though its protective capacity appears overwhelmed in advanced disease stages. Studies in mouse models demonstrate that ATF6 overexpression reduces amyloid burden and improves synaptic function in Alzheimer's disease models, while ATF6 deficiency exacerbates dopaminergic neuron loss in Parkinson's disease models. The ATF6 pathway thus represents a promising therapeutic target for enhancing neuronal resilience to ER stress. [@diego2019][@mercado2020]
Synapses are particularly sensitive to ER stress due to their high local protein synthesis requirements. Synaptic activity demands rapid synthesis and trafficking of synaptic proteins, including neurotransmitter receptors, scaffolding proteins, and components of the release machinery. When ER stress impairs this capacity, synaptic dysfunction ensues before general cellular pathology becomes apparent.
Studies have demonstrated that PERK activation in synapses leads to rapid eIF2α phosphorylation and translational repression. This impairs long-term potentiation (LTP), a cellular correlate of learning and memory, by reducing synthesis of synaptic proteins required for LTP maintenance. Similarly, IRE1/XBP1 signaling regulates synaptic plasticity, with XBP1 deficiency leading to deficits in spatial memory and exploratory behavior. [@harris2019]
Axons present unique challenges for ER quality control due to their length and distance from the soma. Recent work has identified ER stress as a significant contributor to axonal degeneration in neurodegenerative diseases. The axonal ER (axonal ER network) is essential for calcium signaling, lipid metabolism, and local protein synthesis at presynaptic terminals.
In conditions of axonal injury or distal protein aggregation, ER stress propagates from distal axons toward the cell body, ultimately triggering cell death ifunchecked. The PERK-eIF2α pathway appears particularly important in this process, as axonal PERK activation triggers local translation arrest and contributes to "dying-back" neurodegeneration observed in diseases like ALS and peripheral neuropathy. [@polh2022]
ER stress in astrocytes and microglia can influence neuronal health through paracrine signaling. Astrocytes upregulate BiP and other chaperones in response to neuronal injury, potentially providing neuroprotective support. However, chronic neuroinflammation can cause astrocytic ER stress that becomes pathological, releasing inflammatory cytokines that exacerbate neuronal dysfunction. [@ibanez2021]
Microglial ER stress contributes to neuroinflammation through the IRE1-XBP1 pathway, which regulates cytokine production. In neurodegenerative diseases, reciprocal signaling between neurons, astrocytes, and microglia creates feed-forward loops where ER stress in one cell type promotes pathology in others. Understanding these interactions is essential for developing therapies that target the UPR in the context of the entire neural tissue ecosystem. [@ibanez2021][@gerasimenko2019]
Multiple lines of evidence implicate ER stress in Alzheimer's disease pathogenesis. Amyloid-beta (Aβ) oligomers induce ER stress in neurons, activating all three UPR branches. Post-mortem brain tissue from AD patients shows elevated BiP, CHOP, and phosphorylated PERK and IRE1 in neurons surrounding amyloid plaques. [@wang2014][@kim2019]
The PERK-eIF2α pathway appears particularly relevant to AD pathophysiology. Studies in APP/PS1 mice demonstrate that PERK activation in the hippocampus contributes to synaptic dysfunction and memory deficits. Inhibition of PERK or eIF2α phosphorylation rescues synaptic plasticity and improves cognition in these models. However, chronic PERK inhibition may impair adaptive UPR signaling, necessitating careful dosing considerations. [@kim2019][@chitnis2022]
IRE1/XBP1 signaling is also dysregulated in AD, with both hyperactivation and impaired activation reported in different contexts. XBP1s levels are elevated in AD brain, but this may represent a compensatory response that becomes inadequate with disease progression. Interestingly, XBP1 genetic variants have been associated with AD risk, suggesting a potential role for XPR1 variability in disease susceptibility. [@urra2023]
ER stress is a prominent feature of Parkinson's disease, particularly in dopaminergic neurons of the substantia nigra. These neurons are under constant oxidative stress due to dopamine metabolism, making them vulnerable to additional proteotoxic challenges. Alpha-synuclein aggregation—the hallmark pathology of PD—occurs in part within the ER, triggering UPR activation. [@wang2014][@diego2019]
Studies in PD models demonstrate that XBP1 deficiency increases vulnerability of dopaminergic neurons to MPTP toxicity, while XBP1 overexpression is protective. Similarly, ATF6 activation protects against alpha-synuclein-induced neurodegeneration. The PERK-CHOP pathway contributes to dopaminergic neuron death, with CHOP expression elevated in PD brain tissue and PERK inhibitors showing efficacy in cellular models. [@diego2019][@gomez2020]
ER stress is increasingly recognized as a key contributor to motor neuron degeneration in ALS. Mutations in SOD1, FUS, and C9orf72 repeat expansions all cause ER stress in model systems. Motor neurons derived from ALS patient iPSCs show elevated markers of ER stress and impaired UPR adaptive capacity. [@chitnis2022]
The PERK-CHOP pathway is particularly implicated in ALS pathogenesis. Motor neurons exhibit selective vulnerability to PERK-mediated translational repression, and CHOP deletion extends survival in SOD1G93A mice. However, complete PERK inhibition worsens disease in some models, highlighting the complexity of targeting this pathway therapeutically. [@chitnis2022]
Huntington's disease is caused by polyglutamine expansion in the huntingtin protein, which forms aggregates that impair ER function. Chronic UPR activation is observed in HD models and patient tissue, with all three branches showing dysregulation. [@wang2014]
XBP1 deficiency paradoxically improves HD phenotypes in models, suggesting that some UPR branches may be maladaptive in specific disease contexts. This underscores the need for careful, pathway-specific targeting rather than broad UPR modulation. [@gomez2020]
Multiple small molecules targeting UPR components are in development for neurodegenerative diseases. PERK inhibitors (e.g., GSK2606414, ISRIB) have shown efficacy in models, though brain penetration and toxicity remain challenges. IRE1 inhibitors aim to prevent RIDD-mediated RNA degradation while preserving XBP1 splicing. ATF6 activators represent a potentially neuroprotective approach, though few specific activators have been identified. [@cabellos2022]
The UPR modulators that have reached clinical testing include: (1) the PERK inhibitor/dimerizer 4μ8C, (2) the IRE1 RNase inhibitor MKC8866 (formerly 4μ8C analog), and (3) the eIF2α phosphatase inhibitor ISRIB. However, none have yet reached late-stage clinical trials for neurodegenerative disease indications. [@cabellos2022]
Gene therapy offers potential for sustained modulation of UPR components in neurons. AAV-delivered XBP1s has been tested in PD models, showing neuroprotection. CRISPR-based approaches could enable precise modulation of UPR pathway genes or correction of disease mutations that cause ER stress. [@schreder2023]
Rather than modulating UPR sensors directly, therapeutic strategies can target downstream effectors. Autophagy enhancers (e.g., rapamycin, trehalose) promote clearance of misfolded proteins, reducing ER stress burden. Antioxidants mitigate oxidative stress that contributes to protein misfolding. Caspase inhibitors block the apoptotic executioner pathways activated by chronic UPR. [@polh2022]
Current research priorities in neuronal UPR biology include: (1) understanding cell-type specificity of UPR signaling, (2) developing brain-penetrant UPR modulators with acceptable toxicity profiles, (3) identifying biomarkers of UPR activation for patient selection and treatment monitoring, and (4) exploring combinatorial approaches that target multiple branches of the UPR or combine UPR modulation with other therapeutic strategies. [@harris2019][@urra2023]